{"entity":{"id":"werewolf-therapeutics","kind":"company","name":"Werewolf Therapeutics","aka":[],"tldr":"Werewolf makes conditionally activated cytokines (immune signalling proteins such as interleukin-2 and interleukin-12) that are switched on inside tumours. After selling a partnered programme to Jazz, the company agreed in August 2026 to merge with a pain-drug developer, which would end its independent cancer work.","summary":"Werewolf Therapeutics developed INDUKINE molecules, conditionally activated cytokine pro-drugs engineered to be released in the tumour microenvironment, including WTX-124 (IL-2) and WTX-330 (IL-12), both in clinical trials, and JZP898 (IFN-alpha), previously licensed to Jazz Pharmaceuticals. In the second quarter of 2026 Werewolf sold the JZP898 programme to Jazz in a transaction that included a $21.0 million payment, repaid its K2 HealthVentures loan and began a strategic alternatives process with Piper Sandler; cash was $22.0 million at 30 June 2026. On 21 August 2026 Werewolf announced an all-stock merger with Ambros Therapeutics with a concurrent $150 million private placement; the combined company would operate as Ambros Therapeutics in San Diego, focus on neridronate for complex regional pain syndrome and trade as AMBX. The fate of the INDUKINE oncology assets after the merger is not stated in the fetched releases. Nasdaq: HOWL.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://werewolftx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553026000018/a06302026ex991.htm"},{"label":"Merger with Ambros Therapeutics announced (8-K exhibit 99.1, August 2026)","url":"https://www.sec.gov/Archives/edgar/data/1785530/000119312526360059/d102535dex991.htm"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["cytokine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06939283"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Status uncertain: pending reverse merger (announced August 2026) would exit oncology. The $150 million private placement is for the merged Ambros entity and is not listed as a Werewolf round. IPO (2021) not sourced."],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://werewolftx.com/","ticker":"HOWL","stage":"public","investors":[],"funding":[]},"route":"/companies/werewolf-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"trial":[{"id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/"}]}}